Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Targeted IL-2
- Development stage
- Preclinical
- Lead developer
- Iltoo Pharma
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Targeted IL-2 is a preclinical-stage cytokine therapy being developed by Iltoo Pharma using its proprietary ENTAILS (Engineered Tailored Interleukins) platform. The program is designed to engineer interleukin-2 (IL-2) molecules to selectively direct therapeutic activity toward specific immune-cell populations or tissues. By targeting IL-2 activity, the approach aims to maximize the activation of effector immune cells, such as CD8+ T cells and natural killer (NK) cells, while potentially reducing the stimulation of regulatory T cells (Tregs) and minimizing systemic toxicities typically associated with high-dose IL-2 therapy. The specific therapeutic indications for this asset have not yet been disclosed.
- Other names
- ENTAILS Targeted IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)OSE (Oxidation-specific epitope)
Beyond the preview
Go deeper on Targeted IL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Targeted IL-2.